Net Cash Provided by (Used in) Financing Activities in USD of Oncotelic Therapeutics, Inc. from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Oncotelic Therapeutics, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2010 to Q1 2025.
  • Oncotelic Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $160,000, a 36% decline year-over-year.
  • Oncotelic Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $656,000, a 48% decline from 2023.
  • Oncotelic Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $1,250,000, a 11% increase from 2022.
  • Oncotelic Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $1,125,245, a 75% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Oncotelic Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $160,000 -$90,000 -36% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q1 2024 $250,000 +$50,000 +25% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q1 2023 $200,000 -$291,805 -59% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q1 2022 $491,805 -$1,116,395 -69% 01 Jan 2022 31 Mar 2022 10-Q 22 May 2023 2023 Q1
Q1 2021 $1,608,200 +$1,538,200 +2197% 01 Jan 2021 31 Mar 2021 10-Q 23 May 2022 2022 Q1
Q1 2020 $70,000 -$45,000 -39% 01 Jan 2020 31 Mar 2020 10-Q 24 May 2021 2021 Q1
Q1 2019 $115,000 01 Jan 2019 31 Mar 2019 10-Q 29 Jun 2020 2020 Q1
Q1 2014 $20,354,000 +$18,844,000 +1248% 01 Jan 2014 31 Mar 2014 10-Q 08 May 2014 2014 Q1
Q1 2013 $1,510,000 +$1,039,000 +221% 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014 2014 Q1
Q1 2012 $471,000 -$1,154,000 -71% 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013 2013 Q1
Q1 2011 $1,625,000 01 Jan 2011 31 Mar 2011 10-Q 11 May 2012 2012 Q1

Oncotelic Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $656,000 -$594,000 -48% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
2023 $1,250,000 +$124,755 +11% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
2022 $1,125,245 -$3,403,970 -75% 01 Jan 2022 31 Dec 2022 10-K 12 Apr 2024 2023 FY
2021 $4,529,215 +$1,305,159 +40% 01 Jan 2021 31 Dec 2021 10-K/A 20 Apr 2023 2022 FY
2020 $3,224,056 +$1,053,186 +49% 01 Jan 2020 31 Dec 2020 10-K 15 Apr 2022 2021 FY
2019 $2,170,870 +$1,930,870 +805% 01 Jan 2019 31 Dec 2019 10-K 15 Apr 2021 2020 FY
2018 $240,000 01 Jan 2018 31 Dec 2018 10-K 14 May 2020 2019 FY
2013 $9,095,000 +$5,778,000 +174% 01 Jan 2013 31 Dec 2013 10-K 20 Mar 2014 2013 FY
2012 $3,317,000 -$13,837,000 -81% 01 Jan 2012 31 Dec 2012 10-K 20 Mar 2014 2013 FY
2011 $17,154,000 +$6,060,000 +55% 01 Jan 2011 31 Dec 2011 10-K 20 Mar 2014 2013 FY
2010 $11,094,000 01 Jan 2010 31 Dec 2010 10-K 15 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.